Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery.

We report the use of a fragment-based lead discovery method, Tethering with extenders, to discover a pyridinone fragment that binds in an adaptive site of the protein PDK1. With subsequent medicinal chemistry, this led to the discovery of a potent and highly selective inhibitor of PDK1, which binds in the 'DFG-out' conformation.

[1]  D. Boschelli,et al.  Discovery of dibenzo[c,f][2,7]naphthyridines as potent and selective 3-phosphoinositide-dependent kinase-1 inhibitors. , 2007, Journal of medicinal chemistry.

[2]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[3]  J. Briand,et al.  Aminoindazole PDK1 Inhibitors: A Case Study in Fragment-Based Drug Discovery. , 2010, ACS medicinal chemistry letters.

[4]  A. Bridges,et al.  Chemical inhibitors of protein kinases. , 2001, Chemical reviews.

[5]  T. O'Brien,et al.  Fragment-based drug discovery. , 2004, Journal of medicinal chemistry.

[6]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[7]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[8]  D. V. van Aalten,et al.  PDK1, the master regulator of AGC kinase signal transduction. , 2004, Seminars in cell & developmental biology.

[9]  M. Adler,et al.  Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517. , 2007, Bioorganic & medicinal chemistry letters.

[10]  W. Delano,et al.  In situ assembly of enzyme inhibitors using extended tethering , 2003, Nature Biotechnology.

[11]  M. Adler,et al.  Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. , 2007, Bioorganic & medicinal chemistry letters.

[12]  C. Paweletz,et al.  Genetic and Pharmacological Inhibition of PDK1 in Cancer Cells , 2010, The Journal of Biological Chemistry.

[13]  Daniel A Erlanson,et al.  Tethering: fragment-based drug discovery. , 2004, Annual review of biophysics and biomolecular structure.

[14]  R. Stroud,et al.  Site-directed ligand discovery. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Erlanson.  Fragment-based lead discovery: a chemical update. , 2006, Current opinion in biotechnology.

[16]  Marc Adler,et al.  Novel Small Molecule Inhibitors of 3-Phosphoinositide-dependent Kinase-1* , 2005, Journal of Biological Chemistry.

[17]  Daniel A Erlanson,et al.  Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry. , 2008, Bioorganic & medicinal chemistry letters.